Comparsisons among botulinum toxins: An evidence-based review

Plastic and Reconstructive Surgery

Volumn 121, Issue 6, 2008, Pages

  Klein, Arnold W ^a   Carruthers, Alastair ^a   Fagien, Steven ^a   Lowe, Nicholas J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTOXIN; MUSCLE RELAXANT AGENT;

ANHIDROSIS; ARTICLE; BACTERIAL STRAIN; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL EVALUATION; DIPLOPIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTHETICS; EVIDENCE BASED PRACTICE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; PTOSIS; RISK BENEFIT ANALYSIS; SEROTYPE; SKIN STRUCTURE; TREATMENT INDICATION; TREATMENT RESPONSE; WEAKNESS; WRINKLE; AGED; ANIMAL; COMPARATIVE STUDY; CUTANEOUS PARAMETERS; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; ESTHETIC SURGERY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MOUSE; PATIENT SATISFACTION; REVIEW; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

AGED; ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; COSMETIC TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTHETICS; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; RISK ASSESSMENT; SKIN AGING; TREATMENT OUTCOME; UNITED STATES;

EID: 48049103935     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318170813c     Document Type: Article

References (51)

1. Fagien, S. Botulinum toxin type A for facial aesthetic enhancement: Role in facial shaping. Plast. Reconstr. Surg. 112(Suppl.): 6S, 2003.
2. Carruthers, J., Fagien, S., Matarasso, S. L., et al. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast. Reconstr. Surg. 114(Suppl.): 1S, 2004.
3. Klein, A. W. The clinical use of botulinum toxin. Dermatol. Clin. 22: ix, 2004.
4. Botox Cosmetic. Package insert. Irvine, Calif.: Allergan, Inc., 2005.
5. Dysport. Package insert. Berkshire, U.K.: Ipsen Ltd., 2001.
6. Xeomin. Package insert. Frankfurt, Germany: Merz Pharmaceuticals GmbH, 2006.
7. Myobloc. Package insert. South San Francisco, Calif.: Solstice Neurosciences, Inc., 2004.
8. Aoki, K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39: 1815, 2001.
9. Bellew, S. G., Carroll, K. C., Weiss, M. A., and Weiss, R. A. Sterility of stored nonanimal, stabilized hyaluronic acid gel syringes after patient injection. J. Am. Acad. Dermatol. 52: 988, 2005.
10. Aoki, K. R., and Guyer, B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 8(Suppl. 5): 21, 2001.
11. Jankovic, J., Vuong, K. D., and Ahsan, J. Comparison of efficacy and immunogenicity of original versus current bot- ulinum toxin in cervical dystonia. Neurology 60: 1186, 2003.
12. Trindade de Almeida, A. R., Marques, E., de Almeida, J., Cunha, T., and Boraso, R. Pilot study comparing the diffusion of two formulations ofbotulinum toxin type ainpatients with forehead hyperhidrosis. Dermatol. Surg. 33: S37, 2007.
13. Aoki, K. R. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40: 923, 2002.
14. Hambleton, P., Capel, B., Bailey, N., et al. Production, purification and toxoiding of Clostridium botulinum type A toxin. In P. S. Angel and G. E. Lewis (Eds.), Biomedical Aspects of Botulism. New York: Academic Press, 1981.
15. Aoki, K. R. Pharmacology and immunology of botulinum toxin type A. Clin. Dermatol. 21: 476, 2003.
16. Markey, A. C. Dysport. Dermatol. Clin. 22: 213, 2004.
17. Inoue, K., Fujinaga, Y., Watanabe, T., et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 64: 1589, 1996.
18. Friday, D., Bigalke, H., and Frevert, J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature (Abstract). Naunyn Schmiedebergs Arch. Pharmacol. 365: R20, 2002.
19. Schantz, E. J., and Johnson, E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56: 80, 1992.
20. Benecke, R., Jost, W. H., Kanovsky, P., et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64: 1949, 2005.
21. Jost, W. H., Kohl, A., Brinkmann, S., and Comes, G. Efficacy and tolerability of a botulinum toxin type A free of com- plexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox) in healthy volunteers. J. Neural. Transm. 112: 905, 2005.
22. Borodic, G. Therapeutic botulinum toxin. Lancet 344: 1370, 1994.
23. Borodic, G. E., Ferrante, R. J., Pearce, L. B., and Alderson, K. Pharmacology and histology of the therapeutic application of botulinum toxins. In J. Jankovic and M. Hallett (Eds.), Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994.
24. Aoki, R. Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur. J. Neurol. 6: S3, 1999.
25. Aoki, K. R., Satorius, A., Ardila, C., et al. Pharmacology of Botox, Dysport, Myobloc and BTX-A in animal models of efficacy and safety. Abstract presented at the International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Denver, Colorado, June 23-25, 2005.
26. Bihari, K. Safety, effectiveness, and duration of effect of Botox after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm. Curr. Med. Res. Opin. 21: 433, 2005.
27. Blitzer, A., Brin, M. F., Keen, M. S., and Aviv, J. E. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch. Otolaryngol. Head Neck Surg. 119: 1018, 1993.
28. Carruthers, A., and Carruthers, J. The treatment of glabellar furrow with botulinum A exotoxin (Abstract). J. Dermatol. Surg. Oncol. 16: 83, 1990.
29. Kane, M. A. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast. Reconstr. Surg. 103: 656, 1999.
30. Beer, K., Yohn, M., and Closter, J. A double-blinded, placebo- controlled study of Botox for the treatment of subjects with chin rhytids. J. Drugs Dermatol. 4: 417, 2005.
31. Carruthers, A., Carruthers, J., Lowe, N. J., et al. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J. Clin. Res. 7: 1, 2004.
32. Ascher, B., Zakine, B., Kestemont, P., et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J. Am. Acad. Dermatol. 51: 223, 2004.
33. Monheit, G., Carruthers, A., Brandt, F., and Rand, R. A randomized, double-blind, placebo-controlled study of bot- ulinum toxin type a for the treatment of glabellar lines: Determination of optimal dose. Dermatol. Surg. 33: S51, 2007.
34. Fagien, S. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast. Reconstr. Surg. 112: 31S, 2003.
35. Carruthers, J. A., Lowe, N. J., Menter, M. A., et al. A multi-center, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J. Am. Acad. Dermatol. 46: 840, 2002.
36. Ascher, B., Zakine, B., Kestemont, P., et al. Botulinum toxin A in the treatment of glabellar lines: Scheduling the next injection. Aesthetic Surg. J. 25: 365, 2005.
37. Lowe, N. J., Lask, G., Yamauchi, P., and Moore, D. Bilateral, double-blind, randomized comparison of 3 doses of botuli- num toxin type A and placebo in patients with crow's feet. J. Am. Acad. Dermatol. 47: 834, 2002.
38. Levy, J. L., Servant, J. J., and Jouve, E. Botulinum toxin A: A 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study. J. Cosmet. Laser Ther. 6: 16, 2004.
39. Matarasso, A., Matarasso, S. L., Brandt, F. S., and Bellman, B. Botulinum A exotoxin for the management of platysma bands. Plast. Reconstr. Surg. 103: 645, 1999.
40. Lowe, P. L., Patnaik, R., and Lowe, N. J. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol. Surg. 31: 1651, 2005.
41. Lew, H., Yun, Y. S., Lee, S. Y., and Kim, S. J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 216: 50, 2002.
42. Nüssgens, Z., and Roggenkämper, P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch. Clin. Exp. Ophthalmol. 235: 197, 1997.
43. Odergren, T., Hjaltason, H., Kaakkola, S., et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry 64: 6, 1998.
44. Ranoux, D., Gury, C., Fondarai, J., Mas, J. L., and Zuber, M. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 72: 459, 2002.
45. Simonetta Moreau, M., Cauhepe, C., Magues, J. P., and Se- nard, J. M. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br. J. Dermatol. 149: 1041, 2003.
46. Van den Bergh, P. Y., and Lison, D. F. Dose standardization of botulinum toxin. Adv. Neurol. 78: 231, 1998.
47. Marchetti, A., Magar, R., Findley, L., et al. Retrospective evaluation of the dose of Dysport and Botox in the management of cervical dystonia and blepharospasm: The Real Dose study. Mov. Disord. 20: 937, 2005.
48. de Almeida, A., Marques, E., de Almeida, J., Cunha, T., and Boraso, R. Pilot study comparing the diffusion characteristics of two formulations of botulinum toxin type A with forehead hyperhidrosis. Presented at the European Masters in Aesthetic and Anti-Aging Medicine Meeting, Paris, France, September 30-October 2, 2005.
49. Cinzia, L., Francesca, G., Sergio, B., and Alfredo, B. Diffusion of botulinum toxin in facial muscles in patients with hemi- facial spasm (Abstract). Mov. Disord. 20: S175, 2005.
50. Eleopra, R., Tugnoli, V., Caniatti, L., and DeGrandis, D. Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 46: 1158, 1996.
51. Carruthers, A., and Carruthers, J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use. Poster presented at the 13th Congress of the European Academy of Dermatology & Venereology, Florence, Italy, November 17-21, 2004.